Ebalzotan is a selective serotonin (5-HT1A) receptor agonist, was chosen by Astra in the early 1990s as a candidate drug for the treatment of depression and anxiety. It has a modest affinity for the 5-HT(7). In vivo, ebalzotan induced all the typical effects of a 5-HT(1A) receptor agonist in rats: it decreased 5-HT synthesis (5-HTP accumulation) and 5-HT turnover (measured as the ratio of 5-hydroxyindoleacetic acid/5-HT), increased corticosterone secretion, induced the 5-HT(1A) syndrome (flat body posture and forepaw treading), inhibited the cage-leaving response, and caused hypothermia. Ebalzotan had been in phase I clinical trial for the treatment of major depressive disorder. However, this study was discontinued.

Furterene is a diuretic of the aminopteridine series, with aldosterone antagonist activity. Furterene is able to antagonize aldosterone at the mineralocorticoid receptor in the kidneys. It thereby increases sodium excretion while inhibiting potassium excretion.

Benzquercin is a member of flavones. Experiments on mice have shown that compound decreased morphological disorders of the connective tissue of lathyritic mice and the vascular permeability was close to normal controls.

IPSAPIRONE, an azapirone derivative structurally unrelated to the benzodiazepines, is a selective 5-HT1A serotonin receptor agonist. It has antidepressant and anxiolytic effects. IPSAPIRONE was studied in several clinical trials for depression and generalized anxiety disorder.

Ecomustine, or CY233 (NSC-609224), is a water-soluble nitrosoureido derivative of deoxysugar exerting antineoplastic activity. It acts as an alkylating agent. It demonstrated effectivity in the treatment of tumors in animal models.

Prampine is the anticholinergic agent. It was used for the treatment of peptic ulcers. According to the virtual screening, prampine has a good binding affinity with acetylcholinesterase.

Aptocaine (Pirothesin, Pharmaceutical Manufacturing Company) is a new local anaesthetic agent, the first of note to be synthesized in Britain. It is related toprilocaine; like prilocaine, it has a low sub-cutaneous toxicity, but preliminary studies suggest that, unlike prilocaine, it does not induce methaemoglobinaemia. It has been found to produce satisfactory analgesia, of longer duration than lignocaine, by several routes, at a concentration of 3% in animals.

Bamaquimast was developed by Pierre Fabre as an inhibitor of the proton pump with anti-inflammatory and anti-asthmatic effects. This drug participated in phase II clinical trials for the treatment of patients with asthma. However, these studies were discontinued.

Azipramine, an antidepressant, that never been marketed.

Balaglitazone is a second generation peroxisome proliferator-activated receptor (PPAR) gamma agonist with only partial agonistic properties. It passed phase III clinical trial for the treatment of type 2 diabetes. However, Dr. Reddy's Laboratories decided to terminate further clinical development of balaglitazone.